First look: how a breast cancer drug behaves in chinese patients
NCT ID NCT02499146
Summary
This study aimed to understand how the breast cancer drug palbociclib is absorbed and processed in the body of Chinese patients. It involved 26 postmenopausal Chinese women with a specific type of advanced breast cancer. The main goal was to measure drug levels in the blood after single and multiple doses, while also checking for safety and initial signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital/Oncology department
Beijing, Beijing Municipality, 100142, China
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, 100021, China
-
Guangdong General Hospital/Department of Breast Surgery
Guangzhou, Guangdong, 510080, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The first hospital of jilin university
Changchun, Jilin, 130021, China
Conditions
Explore the condition pages connected to this study.